Details for Patent: 7,815,934

Which drugs does patent 7,815,934 protect, and when does it expire?

Patent 7,815,934 protects EMBEDA and TROXYCA ER and is included in two NDAs.

This patent has sixteen patent family members in twelve countries.

Summary for Patent: 7,815,934

Title:	Sequestering subunit and related compositions and methods
Abstract:	A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit and a therapeutic agent in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent.
Inventor(s):	Boehm; Garth (Westfield, NJ)
Assignee:	Alpharma Pharmaceuticals, LLC (Bridgewater, NJ)
Application Number:	10/667,676
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,815,934

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-001	Aug 13, 2009		DISCN	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-002	Aug 13, 2009		DISCN	Yes	No			Y
Alpharma Pharms	EMBEDA	morphine sulfate; naltrexone hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	022321-003	Aug 13, 2009		DISCN	Yes	No			Y

International Family Members for US Patent 7,815,934

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003270778
Australia	2009251081
Canada	2499550